About IONTAS
IONTAS is a Healthcare company based in Cambridge (United Kingdom) founded in 2007 by Peter S, and was acquired by FairJourney Biologics in May 2020. Therapeutic antibody discovery and development services are offered. IONTAS has raised $1.77 million across 2 funding rounds from investors including Gov.uk, Enterprise Ireland and FairJourney Biologics. IONTAS offers products and services including Antibody Discovery, Antibody Engineering, Protein Production, and Biophysical Characterization. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In Vitro Assays.
Company details
IONTAS was founded in 2007 and is based in Cambridge, United Kingdom. Services in therapeutic antibody discovery and development are provided, with a focus on cancer and inflammation areas. Antibody engineering, protein production, and cell line development are offered to biotechnology and pharmaceutical companies. Operations support the creation of novel antibody therapeutics through specialized expertise in the sector.
- Headquarters Cambridge, United Kingdom
- Founders Peter S
- Stage Acquired
- SectorsHealthcare
- Website iontas.co.uk
- Social LinkedIn X YouTube
- Acquired by FairJourney Biologics (May 2020)
- Total Equity Funding$1.77M (USD)
in 2 rounds
- Latest Funding Round$737.88K (USD), Grant
May 2018
- InvestorsGov.uk
& 3 more
- Acquired byFairJourney Biologics
(May 2020)
Products & Services of IONTAS
IONTAS offers a comprehensive portfolio of products and services, including Antibody Discovery, Antibody Engineering, Protein Production, and Biophysical Characterization.
Service for identifying and developing new antibodies.
Modification of antibodies for therapeutic applications.
Production of proteins for research and diagnostics.
Analysis of antibody properties and stability.
Apps and channels of IONTAS
its YouTube channel FairJourney Biologics has 459 subscribers and 30 videos.
Videos from IONTAS
The most watched videos on IONTAS's YouTube channel, FairJourney Biologics (459 subscribers). Click a video to play it here.
More on FairJourney Biologics.
Funding Insights of IONTAS
IONTAS has successfully raised a total of $1.77M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $737.88 thousand completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.77M
- Total Rounds 2
- Last Round Grant — $737,881
- First Round $1.77M
(Jan 2007)
- Investors Count 3
All 2 funding rounds of IONTAS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $737,881 | Grant | – | – | |
| Jan 2007 | $1.77M | Seed | – | – |
4 investors in total: 4 institutional.
Investors in IONTAS
IONTAS has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Enterprise Ireland and FairJourney Biologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided for early-stage Irish companies. | enterpriseequity.ie | Dun Laoghaire, Ireland | ||
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Support is provided to Irish manufacturing and service sector businesses. | 1998 | enterprise-ireland.com | Dublin, Ireland | |
Provider of end to end antibody development services | 2012 | fjbio.com | Porto, Portugal |
Investor details for IONTAS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IONTAS
1 people are tracked at IONTAS (1 in leadership).
| Name | Role | Group |
|---|---|---|
Peter S | Co-Founder & CTO | Leadership |
Complete people profiles for IONTAS
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IONTAS
4 dated milestones of IONTAS across 13 years, from founding to its latest funding, stage changes and deals.
- Founded IONTAS is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Grant, of $738K.
- Exit Acquired by FairJourney Biologics.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iontas
Complete news archive for IONTAS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IONTAS
IONTAS was founded in 2007.
IONTAS is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
IONTAS is a funded company, having raised a total of $1.77M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.77M, raised on Jan 2007.
IONTAS was founded in 2007 and is based in Cambridge, United Kingdom. Services in therapeutic antibody discovery and development are provided, with a focus on cancer and inflammation areas. Antibody engineering, protein production, and cell line development are offered to biotechnology and pharmaceutical companies. Operations support the creation of novel antibody therapeutics through specialized expertise in the sector.
IONTAS offers Antibody Discovery, Antibody Engineering, Protein Production, and Biophysical Characterization.
IONTAS has 4 investors. Key investors include Gov.uk, Enterprise Ireland, FairJourney Biologics, and Enterprise Equity.
Yes. IONTAS was acquired by FairJourney Biologics in May 2020.